Aims : Emerging evidence has linked cholesterol metabolism with platelet responsiveness. We sought to examine the dose–response relationship between low-density lipoprotein cholesterol (LDL-C) and major in-hospital bleeds in acute coronary syndrome (ACS) patients.Methods and results : Among 42 378 ACS patients treated with percutaneous coronary intervention (PCI) enrolled in 240 hospitals in the Improving Care for Cardiovascular Disease in China-ACS project from 2014 to 2019, a total of 615 major bleeds, 218 ischaemic events, and 337 deaths were recorded. After controlling for baseline variables, a non-linear relationship was observed for major bleeds, with the higher risk at lower LDL-C levels. No dose–response relationship was identified for ischaemic events and mortality. A threshold value of LDL-C <70 mg/dL was associated with an increased risk for major bleeds (adjusted odds ratio: 1.49; 95% confidence interval: 1.21–1.84) in multivariable-adjusted logistic regression models and in propensity score-matched cohorts. The results were consistent in multiple sensitivity analyses. Among ticagrelor-treated patients, the LDL-C threshold for increased bleeding risk was observed at <88 mg/dL, whereas for clopidogrel-treated patients, the threshold was <54 mg/dL. Across a full spectrum of LDL-C levels, the treatment effect size associated with ticagrelor vs. clopidogrel on major bleeds favoured clopidogrel at lower LDL-C levels, but no difference at higher LDL-C levels.Conclusions : In a nationwide ACS registry, a non-linear association was identified between LDL-C levels and major in-hospital bleeds following PCI, with the higher risk at lower levels. As the potential for confounding may exist, further studies are warranted.Trial registration: ClinicalTrials.gov Identifier: NCT02306616
13 October 2019 in Oxidative Medicine and Cellular Longevity
Endothelial progenitor cells (EPCs) have the potential to repair damaged blood vessels and promote angiogenesis. Smoking, an important risk factor for cardiovascular diseases, is associated with impaired functions of EPCs. However, the underlying mechanisms remain unclear. The aim of the study was to investigate the effects of cigarette smoke extract (CSE) on autophagy and dysfunction of EPCs and the involvement of galectin-3 in its effects. EPCs were treated with 8% CSE for 24 h (without affecting cell viability). EPC functions were assessed by tube formation and migration capacity and intracellular ROS and eNOS expression. Autophagy was assessed by autophagic protein expression by Western blotting and immunofluorescence microscopy and autophagosome accumulation by transmission electron microscopy. Galectin-3 expression was measured by real-time PCR, Western blotting, and immunofluorescence microscopy, while phospho-AMPK and phospho-mTOR were measured by Western blotting. EPCs were transfected by shRNA-Gal-3 or shRNA-NC before treatment with CSE to examine the effects of galectin-3 on CSE-induced autophagy and dysfunction of EPCs. CSE-treated EPCs showed decreased tube formation and migration ability and eNOS expression but increased oxidative stress. CSE also induced autophagy which was characterized by a decrease in p62 protein, an increase in LC3B-II/I ratio, and accumulation of autophagosomes. CSE upregulated galectin-3 expression on EPCs. Inhibition of galectin-3 abrogated CSE-induced autophagy and dysfunction of EPCs. CSE activated phospho-AMPK and inhibited phospho-mTOR, and inhibition of galectin-3 abolished CSE’s effect on activating phospho-AMPK and inhibiting phospho-mTOR. In conclusion, our results suggest that galectin-3 mediates CSE-induced EPC autophagy and dysfunction, likely via the AMPK/mTOR signaling pathway.
18 November 2025 in Journal of International Medical Research
Objective: Sepsis-induced cardiomyopathy, a life-threatening complication of sepsis, carries a significant mortality risk. Despite its clinical severity, the immunometabolic mechanisms driving its pathogenesis remain poorly understood. This study aimed to identify immunometabolism-associated genes in sepsis-induced cardiomyopathy and analyze immune infiltration. Methods: We integrated single-cell and bulk RNA sequencing data from septic cohorts, using a multistep bioinformatic approach involving machine learning and weighted gene co-expression network analysis to identify key immunometabolism-associated genes and explore their role in sepsis-induced cardiomyopathy. Key findings were validated using in vitro and in vivo experiments. Results: We identified two distinct macrophage subsets (functional and senescent) and prioritized four hub genes, including ABLIM1, BCL9L, SMAD3, and DHRS3, which formed a robust prognostic model (area under the curve = 0.724). In vivo and in vitro validation confirmed significant downregulation of these hub genes in sepsis-induced cardiomyopathy. Immune infiltration analysis demonstrated significant increases in monocytes, M0/M1 macrophages, and neutrophils in sepsis, with hub genes showing significant correlations with specific immune cell subsets. Conclusions: This study identifies ABLIM1, BCL9L, SMAD3, and DHRS3 genes as pivotal biomarkers and potential therapeutic targets in sepsis-induced cardiomyopathy, linked to immune–metabolic dysregulation and myocardial injury. These findings provide new insights for early diagnosis and precision immunotherapy of sepsis-induced cardiomyopathy.
14 July 2026 in Reviews in Cardiovascular Medicine
While restoring blood flow is the primary treatment for acute myocardial infarction (AMI), this process often triggers additional damage known as myocardial ischemia/reperfusion injury (MIRI). Recent studies have suggested that regulated cell death is a major contributor to cardiomyocyte injury during ischemia and subsequent reperfusion. Notably, emerging evidence has demonstrated that both ferroptosis and pyroptosis play important roles in the pathogenesis of MIRI. Ferroptosis is primarily driven by iron-dependent lipid peroxidation, whereas pyroptosis is characterized by inflammasome-mediated inflammatory cell death. However, these processes are typically studied independently, and their potential interactions and shared regulatory mechanisms remain unclear. In this review, we comprehensively summarize the molecular mechanisms underlying ferroptosis and pyroptosis in MIRI. We also discuss emerging evidence supporting the crosstalk between these two processes, with a particular focus on shared upstream triggers such as reactive oxygen species (ROS), mitochondrial dysfunction, and common regulatory proteins, including nuclear factor erythroid 2-related factor 2 (Nrf2), p53, and members of the high mobility group box (HMGB) family. Furthermore, we highlight current therapeutic strategies targeting ferroptosis and pyroptosis and explore the potential of dual-targeting approaches based on their shared signaling pathways. A deeper understanding of the interplay between these two forms of cell death may provide novel insights into the pathogenesis of MIRI and support the development of more effective cardioprotective strategies.
The escalating global burden of cardiovascular disease (CVD) necessitates a deeper elucidation of the fundamental molecular mechanisms driving its pathogenesis. Aberrant immune activation, specifically sterile inflammation, is now recognized as a core hallmark of CVD, predominantly ignited by the pathological accumulation of damaged self-DNA. As the principal cytosolic DNA sensor, the cyclic GMP-AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway has emerged as a crucial mechanistic nexus translating genomic distress into robust innate immune responses. Despite its paramount importance, a comprehensive integration of how DNA damage-induced cGAS-STING activation orchestrates cardiovascular immunology remains underexplored. In this review, we comprehensively synthesize the dynamic immunological landscape of CVD, with a specific focus on the critical interplay between DNA damage and sterile inflammation. We delineate the intricate molecular cascades of the cGAS-STING pathway across diverse cardiovascular pathologies and critically evaluate its role as a master amplifier of disease progression. Furthermore, we highlight the translational trajectory of targeting the cGAS-STING axis, emphasizing how deciphering this DNA damage-immune network provides a rational blueprint for developing precision immunomodulatory therapies in cardiovascular medicine.
20 October 2026 in International Journal for Vitamin and Nutrition Research
Background: Patients remain at substantial residual cardiovascular risk despite standardized management of classical risk factors. These limitations in clinical practice have led to an exposome-based approach. Among environmental exposures, endocrine-disrupting chemicals (EDCs) have emerged as ubiquitous and insidious promoters of cardiometabolic disease. Objectives: This review critically examines chronic environmental exposure to EDCs and the role of these chemicals in cardiovascular injury. In addition, this review highlights how targeted dietary therapies can shift patient management from passive environmental avoidance toward active biological protections. Methods and Results: We review recent mechanistic advances and show that lipophilic EDCs can hijack host signaling networks even at very low exposure levels. These molecular alterations promote mitochondrial dysfunction and global epigenetic reprogramming, leading to proximal metabolic derangements, particularly adipose tissue inflammation, insulin resistance, and atherogenic dyslipidemia. The cardioprotective effects of dietary antioxidants and bioactive phytochemicals appear to arise from intracellular signaling crosstalk. These compounds activate the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant pathway while inhibiting the nuclear factor kappa B (NF-κB) proinflammatory cascade, thereby reducing oxidative stress and endothelial inflammation. Bioactive compounds such as polyphenols, omega-3 fatty acids, and vitamin D may function as nutriepigenetic modulators that counter receptor toxicity and resolve vascular inflammation. Simultaneously, the gut microbiota–vascular axis may act as a biological filter. The Mediterranean diet provides one such holistic intervention by strengthening intestinal barrier function, improving short-chain fatty acid (SCFA) signaling, and reducing pro-atherogenic trimethylamine N-oxide (TMAO) production. Conclusions: EDC exposure disrupts metabolism and can lead to cardiovascular disease. Nutritional approaches targeting the vulnerable human–environment interface can become a proactive chemopreventive shield. Future preventive cardiology may require a significant shift toward precision dietary fortification with an exposome-level risk assessment.